Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128 and Bevacizumab in Recurrent Glioblastoma and Other Solid Tumors
NCT02142803Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sapanisertib in glioblastoma (GBM), solid tumor, endometrial cancer (EC) and 3 more, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 28 days and Most Common Related Toxicities That Led to Dose Hold/Reductions up to 2 years. Started May 2014; status: active, not recruiting.
02
Drugs
sapanisertib
03
Conditions
glioblastoma (GBM)solid tumorendometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02142803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142803.